Figure 1. Schematic diagram depicting theranostic aptamers. Functionalizing aptamers against mutant antigens allows us to deliver theranostics such as imaging agents, drugs, antisense oligonucleotides (ASOs), and extracellular vesicles (EVs) to target cells specifically. This approach can also inhibit the function of mutant intracellular proteins.
Table 1. Immune blockade targets for immunotherapeutic aptamers.
Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?
To request a reprint or corporate permissions for this article, please click on the relevant link below:
Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?
Obtain permissions instantly via Rightslink by clicking on the button below:
If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.
